HK1195733A1 - 抗腫瘤效果增强劑 - Google Patents

抗腫瘤效果增强劑

Info

Publication number
HK1195733A1
HK1195733A1 HK14109161.8A HK14109161A HK1195733A1 HK 1195733 A1 HK1195733 A1 HK 1195733A1 HK 14109161 A HK14109161 A HK 14109161A HK 1195733 A1 HK1195733 A1 HK 1195733A1
Authority
HK
Hong Kong
Prior art keywords
tumor effect
effect potentiator
potentiator
tumor
effect
Prior art date
Application number
HK14109161.8A
Other languages
English (en)
Inventor
福岡正哲
橫川達史
宫原成司
宫腰均
矢野稚子
田口淳子
高尾彌生
Original Assignee
大鵬藥品工業株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大鵬藥品工業株式會社 filed Critical 大鵬藥品工業株式會社
Publication of HK1195733A1 publication Critical patent/HK1195733A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14109161.8A 2009-11-30 2014-09-11 抗腫瘤效果增强劑 HK1195733A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009272738 2009-11-30

Publications (1)

Publication Number Publication Date
HK1195733A1 true HK1195733A1 (zh) 2014-11-21

Family

ID=44066645

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12111795.0A HK1171185A1 (zh) 2009-11-30 2012-11-20 抗腫瘤效果增强劑
HK14109161.8A HK1195733A1 (zh) 2009-11-30 2014-09-11 抗腫瘤效果增强劑

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK12111795.0A HK1171185A1 (zh) 2009-11-30 2012-11-20 抗腫瘤效果增强劑

Country Status (15)

Country Link
US (1) US8883759B2 (zh)
EP (2) EP3673908B1 (zh)
JP (1) JP5336606B2 (zh)
KR (1) KR101701549B1 (zh)
CN (2) CN103948599B (zh)
AU (1) AU2010323454B2 (zh)
BR (1) BR112012013049A2 (zh)
CA (1) CA2782280C (zh)
ES (2) ES2906227T3 (zh)
HK (2) HK1171185A1 (zh)
MX (1) MX2012006183A (zh)
MY (1) MY161094A (zh)
RU (1) RU2548913C2 (zh)
TW (1) TWI466870B (zh)
WO (1) WO2011065541A1 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2295414T1 (sl) * 2008-06-03 2012-12-31 Taiho Pharmaceutical Co., Ltd. Uracilna spojina, ki ima inhibitorno aktivnost za humano deoksiuridin-trifosfatazo, ali njena sol
BR112012013049A2 (pt) 2009-11-30 2016-11-22 Taiho Pharmaceutical Co Ltd potencializador do efeito antitumor.
CA2914178C (en) 2013-01-07 2023-06-13 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2015103489A1 (en) 2014-01-03 2015-07-09 University Of Southern California Heteroatom containing deoxyuridine triphosphatase inhibitors
CN107613983B (zh) * 2015-04-30 2021-05-04 大鹏药品工业株式会社 抗肿瘤剂的副作用减轻剂
WO2016178416A1 (ja) * 2015-05-01 2016-11-10 大鵬薬品工業株式会社 ウラシル化合物の新規結晶
EP3319939A1 (en) 2015-07-08 2018-05-16 CV6 Therapeutics (NI) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
WO2017006271A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
US10577321B2 (en) 2015-07-08 2020-03-03 University Of Southern California Deoxyuridine triphosphatase inhibitors
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用
AU2017205531B2 (en) 2016-01-08 2021-05-13 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator and anti-tumor effect potentiator
WO2018098208A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098209A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US11014924B2 (en) 2016-11-23 2021-05-25 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098204A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018098206A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018128720A1 (en) 2017-01-05 2018-07-12 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
RU2706339C1 (ru) * 2019-07-24 2019-11-18 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ИМЕНИ АКАДЕМИКА А.М. ГРАНОВА" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ им. ак. А.М. Гранова" Минздрава России Способ лечения операбельной аденокарциномы головки поджелудочной железы
JP2023040314A (ja) * 2020-02-18 2023-03-23 大鵬薬品工業株式会社 ウラシル誘導体化合物を含有する抗腫瘍効果増強剤
BR112022026247A2 (pt) 2020-06-26 2023-01-17 Cv6 Therapeutics Ni Ltd Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5839672A (ja) * 1981-09-03 1983-03-08 Chugai Pharmaceut Co Ltd ウラシル誘導体
JPH09286786A (ja) * 1996-04-18 1997-11-04 Nippon Paper Ind Co Ltd ピリミジン誘導体及びその抗腫瘍剤としての用途
RU2102390C1 (ru) * 1996-06-06 1998-01-20 Научно-исследовательская лаборатория иммунохимиотерапии лепры и иммунотропных средств с клиникой и опытно-экспериментальным производством МЗМП России N-(6-метил-2,4-диоксо-1,2,3,4-тетрагидропиримидинил-5-сульфонил) пиразин-2-карбоксамид, обладающий противолепрозной, противотуберкулезной и иммунотропной активностью, способ его получения
GB0400290D0 (en) 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
EP1939186A1 (en) * 2006-12-22 2008-07-02 Sulfidris S.r.l. 5-Fluorouracil derivatives and their use for the treatment of cancer
SI2295414T1 (sl) * 2008-06-03 2012-12-31 Taiho Pharmaceutical Co., Ltd. Uracilna spojina, ki ima inhibitorno aktivnost za humano deoksiuridin-trifosfatazo, ali njena sol
JP2013032293A (ja) * 2009-11-30 2013-02-14 Taiho Yakuhin Kogyo Kk ヒトdUTPase阻害活性を有する5−フルオロウラシル化合物又はその塩
BR112012013049A2 (pt) 2009-11-30 2016-11-22 Taiho Pharmaceutical Co Ltd potencializador do efeito antitumor.
JP5839672B2 (ja) * 2011-09-28 2016-01-06 株式会社日立製作所 低真空軟x線実験装置

Also Published As

Publication number Publication date
MX2012006183A (es) 2012-06-19
ES2906227T3 (es) 2022-04-13
KR101701549B1 (ko) 2017-02-01
US20120225838A1 (en) 2012-09-06
CA2782280C (en) 2019-02-26
CN102612369A (zh) 2012-07-25
MY161094A (en) 2017-04-14
ES2788549T3 (es) 2020-10-21
EP3673908A1 (en) 2020-07-01
RU2012127309A (ru) 2014-01-10
EP2508185A4 (en) 2016-05-25
TW201124387A (en) 2011-07-16
KR20120116925A (ko) 2012-10-23
US8883759B2 (en) 2014-11-11
CN103948599B (zh) 2016-03-09
AU2010323454A2 (en) 2012-06-14
CN102612369B (zh) 2014-06-18
WO2011065541A1 (ja) 2011-06-03
JPWO2011065541A1 (ja) 2013-04-18
BR112012013049A2 (pt) 2016-11-22
AU2010323454B2 (en) 2014-05-08
CN103948599A (zh) 2014-07-30
JP5336606B2 (ja) 2013-11-06
EP3673908B1 (en) 2022-01-12
HK1171185A1 (zh) 2013-03-22
CA2782280A1 (en) 2011-06-03
RU2548913C2 (ru) 2015-04-20
EP2508185A1 (en) 2012-10-10
TWI466870B (zh) 2015-01-01
AU2010323454A1 (en) 2012-06-21
EP2508185B1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
HK1195733A1 (zh) 抗腫瘤效果增强劑
DK3023438T3 (en) Anti-gitr-antistoffer
DK2457337T3 (en) Specialtilpasset impuls-burst
EP2462514A4 (en) GREEN BOOKS
EP2443235A4 (en) ß-glucosidase VARIANTS
EP2515891A4 (en) 3-keto-N-propargyl-1-aminoindan
EP2508411A4 (en) STRUCTURE
EP2519921A4 (en) CALL TRACING
DK2464943T3 (en) Systemintegration
GB201011356D0 (en) Ventalation arrangements
GB0900568D0 (en) Poymerisation
GB0900319D0 (en) Hydrocharger
EP2510125A4 (en) HYPER PRIMER
AU4924P (en) Bonscablue Scaevola aemula
AU4925P (en) Bonscawi Scaevola aemula
AU4926P (en) Bonscalib Scaevola aemula
AU4240P (en) Tuckerbox xTriticosecale
TWM372073U (en) Covering structure
GB0900167D0 (en) B b
PL387107A1 (pl) Profil
GB0921748D0 (en) Switch-actuated arrangements
ZA201008616B (en) Structure
TWM371434U (en) Sun-hat structure
TWM386189U (en) Hanging-painting structure
GB0920959D0 (en) ERoof structure